, NAIROBI, Kenya, Oct 10 – Glaxosmithkline (GSK), has launched a once-daily inhaler for people suffering from asthma.
Relvar Ellipta is an option for patients with adherence problems taking current twice-daily alternatives, and the simplicity of the Ellipta device may also be attractive for patients with poor inhaler technique.
The new medication will see asthma patients take a single dose of the medication for a 24hr efficacy.
“The launch will explore a drug whose data sets are from a first of its kind study and delivered in a novel inhaler platform that has been designed to a high technical specification but most importantly to better meet the needs of patients,” said Bridget Wachira MD GSK Pharmaceuticals Ltd and GM Kenya.
Respiratory disease is a growing problem in Kenya and across Africa with an estimate of about 10 per cent of Kenya’s population living with asthma or COPD, and up to 80pc being uncontrolled.
Despite medical advances globally, more than half of patients (53.5pc) have poor control of their asthma, representing a significant area of unmet medical need.
Furthermore, the number of people with asthma is expected to increase by over a third by 2025, rising to 450 million cases globally.
Wachira cited that the diseases are associated with attacks – exacerbations of the underlying disease, often triggered by infection, where symptoms worsen, breathing becomes even harder and treatment with high dose oral steroids can be required.
“This severely affects a person’s ability to lead a normal life,” noted Wachira. “People with attacks often require an admission to hospital to treat their disease. The mainstay of treatment for improving symptoms and reducing attacks for both asthma and COPD is inhaled medication.”
It is estimated that around 334 million people in the world currently have asthma although this figure could be more as the disease is under-diagnosed and under-treated.